• What we do
  • The People
  • About Us
  • Why Innovation Africa
  • Contact Us
Innovation AfricaCreating the Future Today
  • Feature Articles
  • Innovation
  • Agriculture
  • ICT
  • Technology
  • Entrepreneurship
  • Health
  • Store
  • Contact Us
Menu
  • Feature Articles
  • Innovation
  • Agriculture
  • ICT
  • Technology
  • Entrepreneurship
  • Health
  • Store
  • Contact Us
  • Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.

    January 8, 2016 Editor 0

    Related Articles

    Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.

    Lancet Infect Dis. 2015 Dec 22;

    Authors: De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, Thierry AC, Mayor C, Bailer RT, Mbaya OT, Zhou Y, Ploquin A, Sullivan NJ, Graham BS, Roman F, De Ryck I, Ballou WR, Kieny MP, Moorthy V, Spertini F, Genton B

    Abstract
    BACKGROUND: The ongoing Ebola outbreak led to accelerated efforts to test vaccine candidates. On the basis of a request by WHO, we aimed to assess the safety and immunogenicity of the monovalent, recombinant, chimpanzee adenovirus type-3 vector-based Ebola Zaire vaccine (ChAd3-EBO-Z).
    METHODS: We did this randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a trial at the Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Participants (aged 18-65 years) were randomly assigned (2:2:1), via two computer-generated randomisation lists for individuals potentially deployed in endemic areas and those not deployed, to receive a single intramuscular dose of high-dose vaccine (5 × 10(10) viral particles), low-dose vaccine (2·5 × 10(10) viral particles), or placebo. Deployed participants were allocated to only the vaccine groups. Group allocation was concealed from non-deployed participants, investigators, and outcome assessors. The safety evaluation was not masked for potentially deployed participants, who were therefore not included in the safety analysis for comparison between the vaccine doses and placebo, but were pooled with the non-deployed group to compare immunogenicity. The main objectives were safety and immunogenicity of ChAd3-EBO-Z. We did analysis by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT02289027.
    FINDINGS: Between Oct 24, 2014, and June 22, 2015, we randomly assigned 120 participants, of whom 18 (15%) were potentially deployed and 102 (85%) were non-deployed, to receive high-dose vaccine (n=49), low-dose vaccine (n=51), or placebo (n=20). Participants were followed up for 6 months. No vaccine-related serious adverse events were reported. We recorded local adverse events in 30 (75%) of 40 participants in the high-dose group, 33 (79%) of 42 participants in the low-dose group, and five (25%) of 20 participants in the placebo group. Fatigue or malaise was the most common systemic adverse event, reported in 25 (62%) participants in the high-dose group, 25 (60%) participants in the low-dose group, and five (25%) participants in the placebo group, followed by headache, reported in 23 (57%), 25 (60%), and three (15%) participants, respectively. Fever occurred 24 h after injection in 12 (30%) participants in the high-dose group and 11 (26%) participants in the low-dose group versus one (5%) participant in the placebo group. Geometric mean concentrations of IgG antibodies against Ebola glycoprotein peaked on day 28 at 51 μg/mL (95% CI 41·1-63·3) in the high-dose group, 44·9 μg/mL (25·8-56·3) in the low-dose group, and 5·2 μg/mL (3·5-7·6) in the placebo group, with respective response rates of 96% (95% CI 85·7-99·5), 96% (86·5-99·5), and 5% (0·1-24·9). Geometric mean concentrations decreased by day 180 to 25·5 μg/mL (95% CI 20·6-31·5) in the high-dose group, 22·1 μg/mL (19·3-28·6) in the low-dose group, and 3·2 μg/mL (2·4-4·9) in the placebo group. 28 (57%) participants given high-dose vaccine and 31 (61%) participants given low-dose vaccine developed glycoprotein-specific CD4 cell responses, and 33 (67%) and 35 (69%), respectively, developed CD8 responses.
    INTERPRETATION: ChAd3-EBO-Z was safe and well tolerated, although mild to moderate systemic adverse events were common. A single dose was immunogenic in almost all vaccine recipients. Antibody responses were still significantly present at 6 months. There was no significant difference between doses for safety and immunogenicity outcomes. This acceptable safety profile provides a reliable basis to proceed with phase 2 and phase 3 efficacy trials in Africa.
    FUNDING: Swiss State Secretariat for Education, Research and Innovation (SERI), through the EU Horizon 2020 Research and Innovation Programme.

    PMID: 26725450 [PubMed – as supplied by publisher]

    Go to Source

    Related Posts

    • Why Many Innovation Initiatives Fail
    • Morning Advantage: Why This Start-Up Will Never Promote Another Facebook Post
    • What Should We Do About the eWaste in ICT4D?
    • Smart energy to power refugee campsSmart energy to power refugee camps
    • Ghana: Ghana to Host ITU ConferenceGhana: Ghana to Host ITU Conference
    • Africa: Mapping PhD Enrolment in AfricaAfrica: Mapping PhD Enrolment in Africa
    Sovrn
    Share

    Categories: Health

    Tags: Ebola vaccine

    Restructuring the agricultural supply chain Conservation agriculture for Zambia – A resilient technology in times of climate change

    Leave a Reply Cancel reply

    You must be logged in to post a comment.

Subscribe to our stories


 

Recent Posts

  • SL Crowd Green Solutions September 21, 2020
  • Digital transformation in the banking sector: surveys exploration and analytics August 3, 2020
  • Why Let Others Disrupt You? Take the Smart Self-Disruption Journey! August 3, 2020
  • 5 Tips for Crowdfunding During the Pandemic August 3, 2020
  • innovation + africa; +639 new citations August 3, 2020

Categories

Archives

Popular Post-All time

  • A review on biomass-based... 0.9k views
  • Can blockchain disrupt ge... 669 views
  • Prize-winning projects pr... 646 views
  • Apply Now: $500,000 for Y... 602 views
  • Test Your Value Propositi... 523 views

Recent Posts

  • SL Crowd Green Solutions
  • Digital transformation in the banking sector: surveys exploration and analytics
  • Why Let Others Disrupt You? Take the Smart Self-Disruption Journey!
  • 5 Tips for Crowdfunding During the Pandemic
  • innovation + africa; +639 new citations
  • SME Innovation: 10 Priorities for Support Post-COVID-19 
  • Africa RISING Annual Progress Report 2018 – 2019 now available
  • Fodder beet feed supplementation delivers dairy success for Ethiopian farmers
  • Using theory of change for outcome-oriented research
  • Africa RISING partners publish soil fertility management guidebook

Tag Cloud

    africa African Agriculture Business Business model Business_Finance Company Crowdsourcing data Development East Africa economics Education Entrepreneur entrepreneurs Entrepreneurship ethiopia ghana Health_Medical_Pharma ict Information technology Innovation kenya knowledge Knowledge Management Leadership marketing mobile Mobile phone nigeria Open innovation Organization Research rwanda science Science and technology studies social enterprise social entrepreneurship south africa Strategic management strategy tanzania Technology Technology_Internet uganda

Categories

Archives

  • A review on biomass-based hydrogen production for renewable energy supply 0.9k views
  • Can blockchain disrupt gender inequality? 669 views
  • Prize-winning projects promote healthier eating, smarter crop investments 646 views
  • Apply Now: $500,000 for Your Big Data Innovations in Agriculture 602 views
  • Test Your Value Proposition: Supercharge Lean Startup and CustDev Principles 523 views

Copyright © 2005-2020 Innovation Africa Theme created by PWT. Powered by WordPress.org